Enavogliflozin Improves Adipokine Profile in Type 2 Diabetes
okay, here’s a breakdown of the references provided, formatted for clarity. I’ve extracted the key data from each entry.Reference 42:
Authors: Morciano C, Gugliandolo S, Capece U, Giuseppe G, Mezza T, Ciccarelli G, Soldovieri L, Brunetti M, Avolio A, Splendore A
Title: SGLT2 Inhibition and adipose tissue metabolism: current outlook and perspectives
Journal: Cardiovasc Diabetol
Volume: 23
Issue: 1
Year: 2024
Links:
PubMed: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660748
Google Scholar:
Authors: Xu L, Ota T
Title: Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat Browning and macrophage polarization.
Journal: Adipocyte
Volume: 7
Issue: 2
Year: 2018
Pages: 121-8
Links:
CAS: https://cardiab.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVaisb0%3D
PubMed: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=abstract&list_uids=29376471](